Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03517956
Title	Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)
Acronym	ROCOCO
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Bayer
Indications	Advanced Solid Tumor urethra transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma
Therapies	Copanlisib + Rogaratinib
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| DEU \| BEL